Mealey's (April 30, 2020, 8:39 AM EDT) -- TRENTON, N.J. — The lead plaintiff in a securities class action against a therapeutic products developer and manufacturer and certain of its senior executives failed to sufficiently plead any element of federal securities law claims in arguing that the defendants downplayed adverse side effects of the company’s testosterone replacement therapy drug that were discovered during clinical studies, a federal judge in New Jersey ruled April 28 (Randy Smith v. Antares Pharma Inc., et al., No. 17-8945, D. N.J., 2020 U.S. Dist. LEXIS 74627)....